Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

被引：0

作者：

Duranjou, Marine ^{[1
]}

Castoldi, Cecile ^{[2
]}

Alary, Anne Sophie

Hicheri, Yosr ^{[2
]}

Saillard, Colombe ^{[2
]}

Rouzaud, Camille

Charbonnier, Aude ^{[2
]}

Mohty, Bilal ^{[2
]}

D'Incan, Evelyne ^{[2
]}

Rey, Jerome ^{[2
]}

Devillier, Raynier ^{[3
]}

Vey, Norbert ^{[4
]}

Gelsi-Boyer, Veronique ^{[1
]}

Lhoumeau, Anne-Catherine ^{[1
]}

Murati, Anne ^{[1
]}

Golesi, Florence ^{[1
]}

Mozziconacci, Marie Joelle ^{[1
]}

Ittel, Antoine ^{[1
]}

Garciaz, Sylvain ^{[5
]}

机构：

[1] Inst Paoli Calmettes, Dept Biopathol, Marseille, France

[2] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[3] Aix Marseille Univ, Inst Paoli Calmettes, Hematol & Transplantat, Marseille, France

[4] Aix Marseille Univ, Inst Paoli Calmettes, INSERM,U1068, CNRS,CRCM, Marseille, France

[5] Aix Marseille Univ, Hematol Dept, Integrat Struct & Chem Biol, Inserm,CNRS,Inst Paoli Calmettes,Ctr Rech Cancero, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186086

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
Leroy, Bernard
Fournier, Jean Louis
Ishioka, Chikashi
Monti, Paola
Inga, Alberto
Fronza, Gilberto
Soussi, Thierry
NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
[32] IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC TRASPLANT
Diez Campelo, M.
Caballero, J. C.
del Rey, M.
Janusz, K.
Lumbreras, E.
Abaigar, M.
Robledo, C.
Jerez, A.
Valcarcel, D.
Calderon-Cabrera, C.
Hernandez-Rivas, J. M.
del Canizo, M. C.
HAEMATOLOGICA, 2014, 99 : 348 - 348
[33] Allo-HSCT in Treatment of TP53 Mutation-Related MDS/AML in Pediatric Patients - Report of Two Cases
Deregowski, Maksymilian
Deregowska, Paulina
Sobkowiak-Sobierajska, Agnieszka
Wachowiak, Jacek
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 321 - 322
[34] TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Weinberg, Olga K.
Siddon, Alexa
Madanat, Yazan F.
Gagan, Jeffrey
Arber, Daniel A.
Dal Cin, Paola
Narayanan, Damodaran
Ouseph, Madhu M.
Kurzer, Jason H.
Hasserjian, Robert P.
BLOOD ADVANCES, 2022, 6 (09) : 2847 - 2853
[35] TP53 mutations and MDS - not as easy as it seems
Haase, D.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 7 - 8
[36] REMISSION OF AML IN A PATIENT WITH GERMLINE TP53 MUTATION AFTER DECITABINE MONOTHERAPY
Sadanand, Arhanti
Qayed, Muna
Keller, Frank
PEDIATRIC BLOOD & CANCER, 2022, 69
[37] TP53 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia
Lowe, Scott W.
BLOOD, 2019, 134
[38] MDS with Mono-Allelic TP53 Mutation and Complex Karyotype Shows Similar Prognosis to MDS with Bi-Allelic/Multi-Hit TP53 Lesions
Yabe, Mariko
Weinberg, Olga
Siddon, Alexa
Ouseph, Madhu
Hasserjian, Robert
LABORATORY INVESTIGATION, 2024, 104 (03) : S1505 - S1507
[39] Clinical and Molecular Characterization of Pediatric Acute Myeloid Leukemia with TP53 Alterations
Hara, Yusuke
Taki, Tomohiko
Yamato, Genki
Yoshida, Kenichi
Shiba, Norio
Kaburagi, Taeko
Shiraishi, Yuichi
Ohki, Kentaro
Kawamura, Machiko
Sotomatsu, Manabu
Arakawa, Hirokazu
Matsuo, Hidemasa
Shimada, Akira
Toki, Tsutomu
Kiyokawa, Nobutaka
Tomizawa, Daisuke
Taga, Takashi
Ito, Etsuro
Horibe, Keizo
Miyano, Satoru
Ogawa, Seishi
Adachi, Souichi
Hayashi, Yasuhide
PEDIATRIC BLOOD & CANCER, 2019, 66 : S19 - S20
[40] Interdependency between TP53 mutational status, genetic instability and prognosis in MDS and secondary AML
Schaab, R.
Ganster, C.
Dierks, S.
Parra, Tallo M.
Martin, R.
Germing, U.
Platzbecker, U.
Shirneshan, K.
Lange, F.
Kroeger, N.
Doehner, K.
Glass, B.
Bacher, U.
Haase, D.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 236 - 236

← 1 2 3 4 5 →